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ABSTRACT
In this study we utilized data on patient responses to guided treatments, and 
we evaluated their benefit for a non-small cell lung cancer cohort. The recommended 
therapies used were predicted using tumor molecular profiles that involved a range of 
biomarkers but primarily used immunohistochemistry markers. A dataset describing 
91 lung non-small cell lung cancer patients was retrospectively split into two. The 
first group’s drugs were consistent with a treatment plan whereby all drugs received 
agreed with their tumor’s molecular profile. The second group each received one or 
more drug that was expected to lack benefit. 
We found that there was no significant difference in overall survival or mortality 
between the two groups. Patients whose treatments were predicted to be of benefit 
survived for an average of 402 days, compared to 382 days for those that did not  
(P = 0.7934). In the matched treatment group, 48% of patients were deceased 
by the time monitoring had finished compared to 53% in the unmatched group  
(P = 0.6094). The immunohistochemistry biomarker for the ERCC1 receptor was found 
to be a marker that could be used to predict future survival; ERCC1 loss was found to 
be predictive of poor survival.
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 INTRODUCTION
Lung cancer is the most common cancer in the 
world. Non-small cell lung cancer (NSCLC) is the fourth 
most prevalent cancer in Europe causing 13% of all 
cases, and the third most frequent in the UK. Lung cancer 
incidence is strongly linked with age, in the UK about 
61% of cases are diagnosed in people aged 70 and over. 
Smoking is by far the leading risk factor; about 80% of 
deaths are thought to result from smoking. In the UK, the 
long-term likelihood of developing lung cancer for men is 
about 1 in 13, and for women it is around 1 in 17 [1].
Metastatic NSCLC has traditionally had poor 
outcomes. Metastatic or stage IV NSCLC, has a 5-year 
survival rate of about 1%. In the metastatic disease, 
treatment with cytotoxic chemotherapy is only for 
palliative purposes, and prior to new advances the 
median survival benefit of a course of platinum-based 
chemotherapy was approximately two months [2].
In recent years, targeted treatments and 
immunotherapy (alone or in combination) have been used 
to treat lung cancer. Following identification of activating 
mutations in the EGFR gene in a subset of patients with 
NSCLC, tremendous advances have been made in the use 
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of predictive biomarkers to stratify patients according to 
the oncogenes thought to be driving their malignancy. 
This is most commonly applicable in non-smokers, and 
currently stratification presents a treatment modality in 
approximately 10–20% of patients, depending on ethnicity. 
Somatically acquired mutations in the EGFR gene, or the 
acquisition of a fusion transcript of the EML4-ALK or 
ROS1 oncogenes, have been associated with heightened 
responses to allosteric tyrosine kinase inhibitors that are 
specific to the resultant aberrant kinase. Second and third 
generation kinase inhibitors are now in routine clinical use 
in these subsets of NSCLC. However, if a patient lacks 
a defined mutation in one of these proteins, it is unclear 
whether they will gain from additional molecular testing 
and/or therapy selection.
Previous studies have demonstrated the benefit 
of tumor profiling [3–5] in other types of tumor. Here 
we used data from Caris Life Sciences to see if tumor 
molecular profiling including identification of genetic 
mutations led to better clinical outcomes when used to 
give treatment recommendations in a NSCLC cohort. We 
also looked at the impact of profiling on drug usage.
RESULTS
Historical information about treatments and clinical 
outcomes for 91 advanced stage NSCLC patients taken 
from the Caris CODE database was divided into two groups. 
This was according to if their treatments had matched 
recommendations predicted from their tumor’s molecular 
profile; the recommendations are stated to be mostly obtained 
from previous research identified in the literature.
Treatments were largely related to chemotherapy; 
no patients in this cohort received active immunotherapy; 
and no patients received checkpoint inhibitors prior to 
profiling. Chemotherapy predominated, with only three 
patients receiving no chemotherapy. The 88 patients 
that received it were given 237 chemotherapies (not 
including repeats of the same treatment in a patient). 
Targeted therapies (not including moAbs) were received 
by 20 patients, who received 21 of these treatments, 
while moAbs were given to 32 patients (34 therapies: 31 
bevacizumab and 3 cetuximab).
In the matched treatment group, 42 patients 
were given one or more drugs after sample collection 
for profiling that agreed with their tumor’s molecular 
profile and no treatments predicted to lack benefit. In the 
unmatched treatment group, 49 patients received one or 
more drugs that were expected to lack benefit after the 
time of collection for profiling. Information about the 
demographics of both groups are summarized in Tables 1 
and 2, and Figure 1 (see the plots on the right), along with 
information about the tumors.
The average survival of the two groups is compared 
in Figure 2, in which each bar displayed in the graph 
denotes an individual lung cancer patient and their 
treatments; 42 matched (on the left) and 49 unmatched 
patients (on the right) are shown overall.
Table 3 lists the drugs most frequently given for: 
all patients (total drugs and total treatment periods are 
shown separately); the matched and unmatched groups; 
the most often given drugs predicted to be of benefit; 
lacking benefit; and neither of these. The number of 
patients treated with a drug is shown in the first column, 
and the number of continuous treatment periods is shown 
in all other columns, i.e. treatments of the same patient 
with intervening periods are counted separately. The drugs 
given to the most number of patients were carboplatin 
(74 patients), pemetrexed disodium (41), docetaxel (35), 
and bevacizumab (31). Patients received an average of 
3.73 drugs, of which 34% (115 treatment periods) were 
expected to be of benefit, 24% (80) lacked benefit, and 
42% (144) being neither of these types. Matched patients 
on average had 3.5 drugs-52.7% (1.86 treatments) of these 
were of type benefit, 2% (0.07) lacked benefit, and 45.3% 
(1.60) being neither of these. Unmatched patients had 3.9 
drug treatments on average; 19.4% (0.76 drugs) of these 
were classed as of benefit, 40.3% (1.57) lacked benefit, 
and 40.3% (1.57) neither. Of patients in the unmatched set 
51% had at least one beneficial drug, and 20% received 
two or more drugs of benefit. When comparing the drugs 
given after profiling in the matched group to those given 
when including the time before profiling also, docetaxel 
was given less often after profiling while erlotinib was 
given more frequently.
The most commonly given drugs that when given were 
expected to be of benefit were pemetrexed disodium (23 
treatment periods), carboplatin (22), erlotinib hydrochloride 
(17), and docetaxel (16). The most frequently given lack 
of benefit drug was carboplatin (31). The neither category 
makes up 45% of drugs administered in the matched group, 
compared to 40% in the unmatched group. The most 
popular agents in the neither category were bevacizumab 
(35 treatments, i.e. 10% of drugs overall) and carboplatin 
(30 times). Interestingly, drugs most commonly used in 
metastatic NSCLC, e.g. platinums, were given at similar 
rates independently of whether they were predicted to help.
Overall the drug given most often was carboplatin 
(for 85 time periods over 7845 days in total), although 
following profiling, pemetrexed disodium was given the 
most number of times (26 time periods over 2688 days 
in total).
Patients in the matched group on average survived 
for 402 days after monitoring, compared to 382 days 
for patients in the unmatched group (P = 0.7934). In the 
matched group 48% of patients were deceased when 
monitoring ended, compared to 53% of the unmatched 
group of patients (P = 0.6094). These differences are 
therefore minor and not statistically significant. A Kaplan-
Meier curve showing the overall survival for the matched 
group compared to the unmatched is also shown in Figure 
1 (upper-left).
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Patients who were given more than one drug that 
lacked benefit were found to have a worse overall survival 
(OS) than patients who received only a single drug of this 
type (466.3 versus 318.7 days respectively).
The biomarkers that were used are compared 
between the matched and unmatched groups in Figure 1 
(lower-left), and some were found to be prognostic for 
survival (Figure 3). Most were immunohistochemistry 
(IHC) based markers that have in previous cohorts been 
suggestive of response to cytotoxics, such as etoposide 
(TOPO1), platinum (ERCC1), and fluorouracil (TS). 
Sequencing data for ALK rearrangements and EGFR 
mutations were also included in these predictions. Only 
two patients in this dataset had PD-L1 testing using IHC: 
one patient tested positive, one negative.
DISCUSSION
Here we looked at clinical outcome data for a 
lung cancer cohort provided by Caris Life Sciences, 
in their CODE database. Treatments predicted to be of 
benefit from tumor molecular profiling were proposed 
to clinicians, and the patients who received treatments 
that all agreed with them were compared to those whose 
therapies differed from the recommendations, i.e. they 
had at least one drug that was expected to lack benefit. 
Table 1: Patient ages for the two treatment groups
Age Matched Unmatched
20–29 0 0
30–39 0 0
40–49 4 1
50–59 7 8
60–69 17 19
70–79 9 19
80–89 5 2
Table 2: Summary of patients’ information comparing the matched and unmatched subsets against both combined
Group Patient & Tumor Information
Age Ethnicity Histology Grade Stage Survival (Days)
Mortality 
(%)
All patients 
(91)
66.1 White: 74;
Black/African 
American: 8;
Asian: 6;
Hawaiian/
Pacific 
Islander: 2;
Other/
Unknown: 1
Adenocarcinoma, NOS: 50;
Squamous cell carcinoma, NOS: 19;
Non-small cell carcinoma: 9;
Adenosquamous carcinoma: 3;
Papillary adenocarcinoma, NOS: 2;
Squamous cell carcinoma, 
keratinizing, NOS: 2;
Large cell carcinoma, NOS: 2;
Signet ring cell carcinoma: 1;
Carcinoma, undifferentiated, NOS: 1;
Mucinous adenocarcinoma: 1;
Adenocarcinoma with mixed 
subtypes: 1
Grade 3/ Poorly differentiated: 31 
(34%);
Grade 2/Moderately differentiated: 31 
(34%);
Unknown/Not determined: 13 (14%);
Grade 4/ Undifferentiated: 7 (8%);
Grade 1/Well differentiated: 5 (6%);
None/Not applicable: 4 (4%)
IV: 43 (47%);
III no IIIC: 
25 (28%);
II: 14 (15%);
I: 7 (8%);
Unknown: 2 
(2%)
391 51
Matched 
only (42)
65.1 White: 34;
Asian: 4;
Black/African 
American: 2;
Hawaiian/
Pacific 
Islander: 1;
Other/
Unknown: 1
Adenocarcinoma, NOS: 25;
Squamous cell carcinoma, NOS: 7;
Non-small cell carcinoma: 5;
Adenosquamous carcinoma: 1;
Signet ring cell carcinoma: 1;
Papillary adenocarcinoma, NOS: 1;
Adenocarcinoma with mixed 
subtypes: 1;
Mucinous adenocarcinoma: 1
Grade 2/Moderately differentiated: 17 
(41%);
Grade 3/ Poorly differentiated: 14 
(33%);
Unknown/Not determined: 6 (14%);
None/Not applicable: 2 (5%);
Grade 1/Well differentiated: 2 (5%);
Grade 4/ Undifferentiated: 1 (2%)
IV: 17 (40%);
III no IIIC: 
13 (31%);
II: 7 (17%);
I: 4 (10%);
Unknown: 1 
(2%)
402 48
Unmatched 
(49)
67.1 White: 40;
Black/African 
American: 6;
Asian: 2;
Hawaiian/
Pacific 
Islander: 1
Adenocarcinoma, NOS: 25;
Squamous cell carcinoma, NOS: 12;
Non-small cell carcinoma: 4;
Squamous cell carcinoma, 
keratinizing, NOS: 2;
Adenosquamous carcinoma: 2;
Large cell carcinoma, NOS: 2;
Carcinoma, undifferentiated, NOS: 1;
Papillary adenocarcinoma, NOS: 1
Grade 3/ Poorly differentiated: 17 
(35%);
Grade 2/Moderately differentiated: 14 
(29%);
Unknown/Not determined: 7 (14%);
Grade 4/ Undifferentiated: 6 (12%);
Grade 1/Well differentiated: 3 (6%);
None/Not Applicable: 2 (4%)
IV: 26 (53%);
III no IIIC: 
12 (25%);
II: 7 (14%);
I: 3 (6%);
Unknown: 1 
(2%)
382 53
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Figure 1: Plots of survival, biomarkers, and patient, treatment and tumour characteristics. Upper-left: a Kaplan–Meier 
curve showing overall survival from time of profiling for matched versus unmatched treatment groups. Lower-left: comparison of 
biomarkers between matched and unmatched where positive ratio gives the percentage of cases that have “positive” biomarker results i.e. 
for IHC tests, positive is protein expression above a certain threshold, and for sequencing biomarkers, positive is a gene mutation. The size 
of the circle represents the number of cases. On the right: age of patients, survival time, treatment numbers, and grade of samples, where 
blue is matched patients and red is unmatched patients. 
Figure 2: Patients' treatment schedules and outcomes. Treatment plans for the 42 matched patients shown in ascending post-
profiling survival time are shown on the left (darker background), and for the 49 unmatched patients are on the right (lighter background). 
The ordinate is time in days where the axis is the time of profiling. Gray = total time monitored from diagnosis; a black line at the top of a 
column is death; green = time on a drug of benefit; red = lack of benefit treatment; yellow = combination therapy including benefit and lack 
of benefit drugs; blue = neutral therapy (neither benefit nor lack of benefit).
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The biomarkers profile was generally IHC-based in this 
cohort, and as such drew on evidence from previous 
studies that associated levels of key proteins in the tumor 
with responses to particular classes of cytotoxics, e.g. 
thymidylate synthetase levels with fluorouracil (5FU) 
response. Mutational analyses were restricted to a panel 
of 45 genes such as EGFR, ALK, KRAS, NOTCH1, 
PIK3CA, PTEN and TP53. Comparing the two groups 
indicated that the matched group had an increase of 5% 
in survival compared to an unmatched group on average, 
and an increase of 20 days i.e. 402 versus 382 days. There 
was therefore a trend towards increased survival in the 
matched group, but this was not statistically significant. It 
would be interesting to know if any patients had more than 
one Caris test performed sequentially after progression, 
and how the results compared, but this information was 
not available in the dataset that we used.
The unmatched group received 0.4 more therapies 
than the matched group on average, and survived for less 
time. This could be because the unmatched group had tumors 
that were more advanced than those from the matched group 
(e.g. 26 vs 17 stage IV tumors respectively-see Table 2). 
The unmatched group adhered less to the recommended 
treatments largely due to the use of platinums. This is likely 
because platinum-based doublets remain standard evidence-
based therapeutics in NSCLC, with clinicians seeing them as 
Table 3: The most frequently given drugs by treatment group and those predicted to be of benefit, lacking benefit, 
or neither, listed in descending order
Number 
of Patients 
Treated
Most Frequently Administered Drugs (Total Treatment Periods)
All patients 
treated
All patients 
-treatment 
periods
Matched only 
patients, all 
treatments
Matched, 
after profiling 
treatments only
Unmatched 
patients, all 
treatments
Unmatched, 
after profiling 
treatments only
Drugs 
predicted of 
benefit
Drugs 
predicted to 
lack benefit
Drugs with no 
prediction (neither 
of benefit or lack 
of benefit)
carboplatin - 74 
patients
carboplatin: 
85
carboplatin: 36 pemetrexed 
disodium: 13
carboplatin: 49 pemetrexed 
disodium: 13
pemetrexed 
disodium: 23
carboplatin: 
31
bevacizumab: 35
pemetrexed 
disodium - 41 
patients
pemetrexed 
disodium: 48
pemetrexed 
disodium: 21
erlotinib 
hydrochloride: 11
pemetrexed 
disodium: 27
bevacizumab: 12 carboplatin 22 pemetrexed 
disodium: 10
carboplatin: 30
docetaxel - 35 
patients
docetaxel: 39 docetaxel: 20 carboplatin: 10 bevacizumab: 
22
carboplatin: 11 erlotinib 
hydrochloride: 
17
docetaxel; 
gemcitabine 
hydrochloride;
cisplatin: 8
pemetrexed 
disodium;
docetaxel: 15
bevacizumab - 
31 patients
bevacizumab: 
38
bevacizumab: 
16
bevacizumab: 8 docetaxel: 19 gemcitabine 
hydrochloride: 10
docetaxel: 16 - -
paclitaxel - 23 
patients
paclitaxel; 
erlotinib 
hydrochloride: 
24
erlotinib 
hydrochloride: 
13
docetaxel: 5 paclitaxel: 17 erlotinib 
hydrochloride; nab-
paclitaxel: 6
gemcitabine 
hydrochloride: 
9
- paclitaxel: 13
gemcitabine 
hydrochloride - 
21 patients
- paclitaxel;
cisplatin :7
capecitabine; 
cisplatin; 
gemcitabine 
hydrochloride: 2
gemcitabine 
hydrochloride: 
16
- paclitaxel; 
nab-paclitaxel: 
7
erlotinib 
hydrochloride: 
6
cisplatin; 
vinorelbine tartrate: 
6
cisplatin; 
erlotinib 
hydrochloride - 
17 patients
gemcitabine 
hydrochloride: 
22
- - cisplatin: 13 cisplatin; docetaxel: 
4
- paclitaxel: 4 -
- cisplatin: 20 gemcitabine 
hydrochloride: 
6
- erlotinib 
hydrochloride: 
11
- cisplatin: 5 cetuximab; 
nab-
paclitaxel: 2
etoposide: 5
nab-paclitaxel - 
10 patients
nab-
paclitaxel: 11
nab-paclitaxel: 
4
vinorelbine 
tartrate; 
fluorouracil; 
cetuximab; 
irinotecan 
hydrochloride; 
afatinib dimaleate; 
paclitaxel; 
nab-paclitaxel; 
leucovorin 
calcium: 1
nab-paclitaxel: 
7
vinorelbine tartrate: 
3
bevacizumab;
crizotinib: 2
- gemcitabine 
hydrochloride: 4
vinorelbine 
tartrate - 6 
patients
vinorelbine 
tartrate: 6
fluorouracil; 
cetuximab;
capecitabine;
etoposide: 2
- vinorelbine 
tartrate: 5
crizotinib; 
paclitaxel 2
- crizotinib: 1 fluorouracil: 2
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a backbone of therapy. Practitioners are therefore reluctant 
to discard these agents, even in the presence of a molecular 
profile suggesting carboplatin may be less efficacious in a 
particular patient, e.g. given loss of ERCC1 expression. This 
may reflect the controversy and mixed reports surrounding 
this biomarker, with recent data showing unclear prognostic 
significance [6].
As this panel was historical, many notable 
prognostic biomarkers that would be considered useful 
today, such as FGFR1 or FGFR3 amplification, RET, 
MET, DDR, KRAS, BRAF and PIK3CA, were not included 
for the selection of targeted therapy in the NSCLC 
cohort. All of these oncogenes have potential associated 
therapeutic treatments. Indeed a large proof of concept 
phase 3 study in France that used a panel including the 
majority of the above genes to stratify over seventeen 
thousand patients with NSCLC, showed that about half of 
all patients had a mutation in one of the above genes, and 
these patients had better response rates to first and second 
line treatments, and better survival [7].
Overall this study shows limited benefits from 
performing IHC-based profiling of NSCLC patients 
to determine response to cytotoxic chemotherapy. It is 
clear that clinicians rely heavily on cytotoxics when no 
molecularly targeted agent is appropriate, and are reluctant 
to implement the suggested regimens on the basis of IHC-
Figure 3: Volcano plots that show biomarkers’ prognostic value for a lung cancer dataset. Red dots indicate the hazard rate 
of a positive biomarker result is significantly higher than that of a negative biomarker result, green shows that the hazard rate of a positive 
biomarker result is significantly lower than that of a negative biomarker result, gray shows that the difference between a positive and 
negative result is not significant. Immunohistochemistry biomarkers with the notable DNA excision repair protein ERCC1 are shown in the 
upper plot. Biomarkers derived from sequencing are displayed in the lower plot, and although there are only three sequencing markers, the 
epidermal growth factor receptor (EGFR) shows good prognostic ability.
Oncotarget12811www.impactjournals.com/oncotarget
based molecular markers that have had at best mixed 
evidence. We see a lack of difference in survival of non-
small cell lung cancer patients according to treatment 
selection in this molecular characterization cohort. This 
may be due to the small sample size and limited number 
of validated biomarkers being explored in the biomarker 
panel here. In this cohort of patients, ERCC1 loss was 
predictive of poor survival (Figure 3), and we would 
recommend extending routine profiling in NSCLC patients 
to include clinically actionable driver oncogenes that have 
been demonstrated to enable selection of appropriate 
targeted therapies beyond cytotoxic chemotherapy.
METHODS
The Caris CODE database (Comprehensive 
Oncology Database Explorer) contains tumor molecular 
profile data for 841 patients with solid tumors (CODE 
version 1.0). It also contains demographic information 
about these patients, the drug treatments that they received 
before and after molecular profiling and records of their 
clinical outcomes while they were still being monitored. 
There are 91 lung non-small cell lung cancer patients 
within this database, and this lung cancer cohort was 
mined after web scraping to extract the data from their 
website, to understand if molecular characterization 
affected drug selection by treating physicians, and if any 
molecular subsets had different outcomes across tumor 
types. Tables 1 and 2 describe the clinical characteristics 
of the patients that were profiled. According to Caris, 46% 
of patients had a metastatic sample profiled in this dataset.
Although the amount of time that patients were 
monitored varied-as shown in Figure 2-on average 
patients’ treatment records were available for 654 days 
after diagnosis (737 for matched treatment patients, 583 
for unmatched). The time of monitoring after profiling was 
391 days on average, and the longest period of monitoring 
after profiling was 1683 days (the patient represented 
on the furthest right of Figure 2) which was 1734 days 
after diagnosis. The longest amount of time that treatment 
records were available after diagnosis was 5242 days.
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